Anti-IgE treatment: An update

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 56, Issue 12, 2001, Pages 1121-1128

  Babu, K S ^a   Arshad, S H ^a   Holgate, S T ^a  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FC RECEPTOR; HUMAN MONOCLONAL ANTIBODY; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E RECEPTOR; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; LEVOFLOXACIN; OMALIZUMAB; PLACEBO; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ALLERGIC ASTHMA; ALLERGIC RHINITIS; ALLERGY; ANTIGENICITY; ANTIINFLAMMATORY ACTIVITY; ASTHMA; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RESPIRATORY TRACT INFECTION; REVIEW; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTI-ALLERGIC AGENTS; ANTIBODIES, MONOCLONAL; ASTHMA; CHILD; CLINICAL TRIALS, PHASE III; HUMANS; IMMUNOGLOBULIN E; RESPIRATORY HYPERSENSITIVITY; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL;

EID: 0035192144     PISSN: 01054538     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1398-9995.2001.00019.x     Document Type: Review

References (53)

1. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC
2. Prevalence and etiology of asthma
3. Changing prevalence of allergic rhinitis and asthma
4. Consensus statement on the treatment of allergic rhinitis
5. Bronchial asthma
6. How much asthma is really attributable to atopy?
7. The role of intervention in established allergy: Avoidance of indoor allergens in the treatment of chronic allergic disease
8. Nasal mast cells in perennial allergic rhinitics exhibit increased expression of the Fc epsilonRI, CD40L, IL-4, and IL-13, and can induce IgE synthesis in B cells
9. Dendritic cells in normal and asthmatic airways: Expression of the α subunit of the high affinity immunoglobulin E receptor (FcεRI-α)
10. The high-affinity IgE receptor (FcepsilonRI) blocks apoptosis in normal human monocytes
11. Functional and phenotypic differences of monocyte-derived dendritic cells from allergic and nonallergic patients
12. The high affinity IgE receptor (FcεRI) mediates IgE-dependent allergen presentation
13. FcεRI on dendritic cells: A receptor which links IgE mediated allergic reaction and T cell mediated cellular response
14. Enhanced expression of high-affinity IgE receptor (FcεRI) α chain in human allergen-induced rhinitis with co-localization to mast cells, macrophages, eosinophils, and dendritic cells
15. Increased expression of high affinity IgE (FcεRI) receptor-α chain mRNA and protein-bearing eosinophils in human allergen-induced atopic asthma
16. IgE receptors on human eosinophils
17. Expression of the high-affinity receptor for IgE on bronchial epithelial cells of asthmatics
18. Expression of high-affinity IgE receptors (FcεRI) on peripheral blood basophils, monocytes, and eosinophils in atopic and nonatopic subjects: Relationship to total serum IgE concentrations
19. Molecular concepts of IgE-initiated inflammation in atopic and nonatopic asthma
20. High-affinity IgE receptor (FcεRI)-bearing cells in bronchial biopsies from atopic and nonatopic subjects
21. Elevation of total serum immunoglobulin E is associated with asthma in nonallergic individuals
22. Immunopathology and human mast cell cytokines
23. Treatment of allergic asthma with monoclonal anti-IgE antibody
24. rhuMAb-E25 (E25), a novel therapy for the treatment of allergic asthma
25. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics
26. The efficacy and safety of rhuMAb-E25 in children with allergic asthma
27. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis
28. rhuMAb-E25 in the treatment of seasonal allergic rhinitis (SAR)
29. Relationship between the clinical efficacy of rhuMAb-E25 (E25) and serum free IgE in seasonal allergic rhinitis
30. Humanization of an antibody directed against IgE
31. The binding site on human immunoglobulin E for its high affinity receptor
32. Inhibition of allergic reactions with antibodies to IgE
33. Down-regulation of FcεRI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody
34. Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response
35. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects
36. IgE - A marker of the late asthmatic response?
37. Anti-inflammatory effects of a recombinant monoclonal anti-IgE (E25) in asthma
38. A pilot study of the effects of an anti-IgE antibody (E25) on airway inflammation in moderate-severe asthma
39. Structure of the Fc fragment of human IgE bound to its high-affinity receptor FcεRIα
40. Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE
41. Tissue distribution and complex formation with IgE of an anti-IgE antibody after intravenous administration in cynomolgus monkeys
42. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis
43. Effect of aerosolized anti-IgE (E25) on airway responses to inhaled allergen in asthmatic subjects
44. 1 in asthma patients compared to placebo
45. Measuring quality of life in asthma
46. Measuring quality of life in children with asthma
47. Determining a minimal important change in a disease-specific quality of life questionnaire
48. rhuMAb-E25 improves asthma-specific quality of life in patients with allergic asthma
49. rhuMAb-E25 (E25) improves quality of life (QoL) in children with allergic asthma
50. Omalizumab demonstrates inhaled corticosteroid (ICS) sparing in asthma across a range of disease severities
51. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis
52. Safety of readministration of rhuMAb-E25 in seasonal allergic rhinitis (SAR)
53. Xolair® in the treatment of perennial allergic rhinitis